Table 2.
Baseline characteristics of patients receiving MR vs ASCT
| MR (n = 44) | ASCT (n = 22) | P value* | |
|---|---|---|---|
| Age | |||
| Median (range) | 63 (40-76) | 57 (48-68) | .02 |
| WBC (×1000), per mm3 | |||
| Median (range) | 6.7 (4.2-57.7) | 7.5 (3.0-48.8) | .16 |
| Unknown | 2 | 1 | |
| Performance status | |||
| 0 | 26 (59%) | 18 (82%) | .21 |
| 1 | 16 (36%) | 4 (18%) | |
| 2 | 2 (5%) | 0 (0%) | |
| Lactate dehydrogenase | |||
| Elevated | 17 (40%) | 6 (27%) | .42 |
| Not elevated | 26 (60%) | 16 (73%) | |
| Unknown | 1 | 0 | |
| MIPI | |||
| Low risk | 16 (39%) | 10 (48%) | .74 |
| Intermediate risk | 16 (39%) | 8 (38%) | |
| High risk | 9 (22%) | 3 (14%) | |
| Unknown | 3 | 1 | |
| VcR-CVAD response | |||
| CR | 31 (70%) | 20 (91%) | .07 |
| PR | 13 (30%) | 2 (9%) | |
WBC, white blood cell.
*
P values were based on Wilcoxon rank-sum tests for continuous variables and on Fisher exact tests for categorical variables.